Stock Scorecard



Stock Summary for Bristol-Myers Squibb Company (BMY) - $48.18 as of 5/13/2025 10:18:49 AM EST

Total Score

12 out of 30

Safety Score

61 out of 100

Currently on the following lists
None
Tim's Recommendation
Avoid

Growth List Algorithm Criteria for BMY

Positive earnings growth
P/E ratio less than Industry P/E Ratio
P/E ratio less than Sector P/E Ratio
P/E ratio that is half the growth rate (or less)
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Positive net income past year and 12 trailing months
Free cash flow ratio greater than 0 and less than 10

Small Cap List Algorithm Criteria for BMY

Revenue growing by at least 20% average per year over the last 5 years
Market Capitalization under 2 billion
Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months
Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months
Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year

Dividend List Algorithm Criteria for BMY

Declared an ex-dividend date
Forward annual dividend rate greater than 2
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Current ratio most recent quarter greater than 2
Cash Flow per Share greater than Trailing Dividend Rate

Bonus Criteria for BMY

P/E ratio less than five-year Average P/E ratio
Last Price to 52 Week Low Ratio Less Than 1
Total Cash Per Share > Last Day Price
P/S Ratio < 1
P/B Ratio < 1

Safety Rating Criteria for BMY (61 out of 100)

Stock Price Rating (Max of 10) 8
Historical Stock Price Rating (Max of 10) 9
Stock Price Trend (Max of 10) 0
Book Value (Max of 10) 4
Book Value to Price (Max of 10) 0
Analyst Buy Ratings (Max of 5) 3
Analyst Strong Buy Ratings (Max of 5) 5
Dividend Yield Percentage (Max of 10) 8
Operating Margin (Max of 10) 6
Trading Volume (Max of 10) 10
Price to Earnings (Max of 10) 8
Geopolitical Risk Adjustment (Always 0 for USA or a Negative Number for Non-USA) 0

Latest News for for BMY

Even Pharma Rallied On Monday - SPDR Select Sector Fund - Health Care ( ARCA:XLV ) 5/13/2025 1:23:00 PM
Should SPDR Russell 1000 Low Volatility Focus ETF ( ONEV ) Be on Your Investing Radar? 5/13/2025 10:20:00 AM
Trump wants to slash U.S. drug prices with 'most favored nation' policy - here's what to know 5/12/2025 7:54:00 PM
Profiting From A Pharma Panic 5/12/2025 3:50:00 PM
EXCLUSIVE: FDA Clears Lantern Pharma's Planned Phase 1b/2 Trial of LP-184 In Treatment-Resistant Lung Cancer Patients - Lantern Pharma ( NASDAQ:LTRN ) 5/12/2025 12:31:00 PM
CytomX Therapeutics Announces Pricing of $100 Million Underwritten Offering of Common Stock - CytomX Therapeutics ( NASDAQ:CTMX ) 5/12/2025 10:50:00 AM
CytomX Therapeutics Announces First Quarter 2025 Financial Results and Provides Business Update 5/12/2025 10:15:00 AM
CytomX Therapeutics Announces First Quarter 2025 Financial Results and Provides Business Update - CytomX Therapeutics ( NASDAQ:CTMX ) 5/12/2025 10:15:00 AM
CytomX Announces Positive Interim Data From Phase 1 Dose Escalation Study of EpCAM Antibody Drug Conjugate ( CX-2051 ) Candidate in Patients with Advanced Colorectal Cancer ( CRC ) 5/12/2025 10:15:00 AM
Generic Drugs Market size is projected to reach USD 594.99 billion by 2031, With growing at a CAGR of 5.0% | The Insight Partners 5/9/2025 2:31:00 PM

Financial Details for BMY

Company Overview

Ticker BMY
Company Name Bristol-Myers Squibb Company
Country USA
Description Bristol Myers Squibb (BMS) is an American multinational pharmaceutical company, headquartered in New York City. Bristol Myers Squibb manufactures prescription pharmaceuticals and biologics in several therapeutic areas, including cancer, AIDS, cardiovascular disease, diabetes, hepatitis, rheumatoid arthritis and psychiatric disorders.
Sector Name LIFE SCIENCES
Industry Name PHARMACEUTICAL PREPARATIONS
Most Recent Quarter 3/31/2025
Next Earnings Date 7/31/2025

Stock Price History

Last Day Price 48.18
Price 4 Years Ago 54.37
Last Day Price Updated 5/13/2025 10:18:49 AM EST
Last Day Volume 25,598,873
Average Daily Volume 16,421,912
52-Week High 62.65
52-Week Low 37.77
Last Price to 52 Week Low 27.56%

Valuation Measures

Trailing PE 17.33
Industry PE 30.10
Sector PE 47.92
5-Year Average PE 20.81
Free Cash Flow Ratio 9.02
Industry Free Cash Flow Ratio 18.49
Sector Free Cash Flow Ratio 30.82
Current Ratio Most Recent Quarter 1.28
Total Cash Per Share 5.34
Book Value Per Share Most Recent Quarter 8.54
Price to Book Ratio 5.57
Industry Price to Book Ratio 35.42
Sector Price to Book Ratio 27.83
Price to Sales Ratio Twelve Trailing Months 1.98
Industry Price to Sales Ratio Twelve Trailing Months 89.39
Sector Price to Sales Ratio Twelve Trailing Months 25.47
Analyst Buy Ratings 3
Analyst Strong Buy Ratings 5

Share Statistics

Total Shares Outstanding 2,035,080,000
Market Capitalization 98,050,154,400
Institutional Ownership N/A

Dividends

Ex-Dividend Date 4/4/2025
Previous Dividend Amount 0.6200
Current Dividend Amount 0.6200
Total Years Dividend Increasing 3
Trailing Annual Dividend Rate 2.44
Trailing Annual Dividend Yield 5.25%
Forward Annual Dividend Rate 2.48
Forward Annual Dividend Yield 5.34%
5-Year Dividend Payments Count 20
3-Year Average Dividend Yield 4.34%
5-Year Average Dividend Yield 4.20%
1-Year Dividend Growth Rate Percentage 3.33%
3-Year Dividend Growth Rate Percentage 1.65%
5-Year Dividend Growth Rate Percentage 2.01%
All-Time Dividend Growth Rate Percentage 7.25%
Dividend Payout Ratio 91.04%

Income Statement

Quarterly Earnings Growth YOY -95.90%
Annual Earnings Growth -211.50%
Reported EPS 12 Trailing Months 2.68
Reported EPS Past Year 1.80
Reported EPS Prior Year 1.14
Net Income Twelve Trailing Months 5,419,000,000
Net Income Past Year -8,948,000,000
Net Income Prior Year 8,025,000,000
Quarterly Revenue Growth YOY -5.60%
5-Year Revenue Growth 13.06%
Operating Margin Twelve Trailing Months 31.60%

Balance Sheet

Total Cash Most Recent Quarter 10,875,000,000
Total Cash Past Year 10,346,000,000
Total Cash Prior Year 11,464,000,000
Net Cash Position Most Recent Quarter -35,282,000,000
Net Cash Position Past Year -37,257,000,000
Long Term Debt Past Year 47,603,000,000
Long Term Debt Prior Year 36,653,000,000
Total Debt Most Recent Quarter 46,157,000,000
Equity to Debt Ratio Past Year 0.26
Equity to Debt Ratio Most Recent Quarter 0.27
Total Stockholder Equity Past Year 16,335,000,000
Total Stockholder Equity Prior Year 29,430,000,000
Total Stockholder Equity Most Recent Quarter 17,389,000,000

Free Cash Flow

Free Cash Flow Twelve Trailing Months 13,086,000,000
Free Cash Flow Per Share Twelve Trailing Months 6.43
Free Cash Flow Past Year 13,942,000,000
Free Cash Flow Prior Year 12,651,000,000

Options

Put/Call Ratio 1.24
Has Options Options Chain
Liquidity Rating

Technical Analysis

Yahoo Finance Chart Yahoo Finance Chart
MACD -1.94
MACD Signal -1.94
20-Day Bollinger Lower Band 46.05
20-Day Bollinger Middle Band 54.73
20-Day Bollinger Upper Band 63.42
Beta 0.40
RSI 31.50
50-Day SMA 51.09
150-Day SMA 55.48
200-Day SMA 56.25

System

Modified 5/12/2025 7:13:51 PM EST